Welcome to our dedicated page for Shake Shack SEC filings (Ticker: SHAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shake Shack鈥檚 signature crinkle-cut fries may be simple, but the company鈥檚 regulatory disclosures aren鈥檛. On this page you鈥檒l find every SEC document鈥攆rom the Shake Shack annual report 10-K simplified to real-time Shake Shack Form 4 insider transactions鈥攊ndexed and decoded by Stock Titan鈥檚 AI.
Use our platform to understand how beef prices flow through cost of goods sold, how new shack openings impact lease obligations, and where executive incentives align with margin expansion. Our AI-powered summaries break down Shake Shack quarterly earnings report 10-Q filing line items, spotlight footnotes on commodity hedging, and translate accounting language into plain English. Whether you鈥檙e comparing same-shack sales or monitoring Shake Shack executive stock transactions Form 4, the answers surface in seconds.
Common questions investors ask鈥斺�淗ow did labor costs move this quarter?鈥�, 鈥淲hat鈥檚 inside the latest Shake Shack proxy statement executive compensation?鈥�, 鈥淲as there a recent Shake Shack 8-K material events explained?鈥濃�攁re built directly into our search prompts. You鈥檒l also receive instant alerts on Shake Shack insider trading Form 4 transactions and board changes, plus red-lined comparisons across periods for deeper Shake Shack earnings report filing analysis.
- AI summaries that explain complex sections in under a minute
- AG真人官方-time updates from EDGAR, including Shake Shack SEC filings explained simply
- Keyword search across risk factors, franchise revenues, and capital expenditures
Stop paging through PDFs; start understanding Shake Shack SEC documents with AI and make confident decisions with the full picture in view.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has filed a Rule 424(b)(5) prospectus supplement establishing a US$50 million at-the-market (ATM) equity program through A.G.P./Alliance Global Partners. Under the July 3 2025 Sales Agreement, A.G.P. will act as sales agent on a best-efforts basis and receive a 3.0% commission on gross proceeds. No minimum drawdown is required and proceeds will not be placed in escrow.
The facility allows Tevogen to issue primary common shares (par $0.0001) from time to time at prevailing market prices. At the July 2 2025 closing price of US$1.25, management illustrates a scenario in which up to 40.0 million new shares could be issued, increasing basic shares outstanding from 184.4 million to 224.4 million (鈮�22% dilution).
Use of proceeds is intentionally broad: working capital, R&D (including ExacTcell鈩� and Tevogen.AI initiatives), capital expenditures, debt repayment, M&A, and other general corporate purposes. The company retains full discretion over timing and sizing of individual placements.
Balance-sheet impact & dilution. As of March 31 2025 Tevogen reported negative net tangible book value (NTBV) of US$(7.7)m, or US$(0.04) per share. Assuming the full US$50 million raise at US$1.25 per share (less 3% fees and estimated US$70k expenses) NTBV would improve to approximately US$40.7 million, or US$0.18 per share, implying immediate dilution of US$1.07 per share to new investors. Additional dilution is possible from: (i) 500k Series A and 4.54 m Series C preferred conversions; (ii) 1.14 m vested RSUs; and (iii) future financings.
Key risks disclosed include: substantial additional capital needs ahead of clinical and AI initiatives; potential constraints imposed by outstanding preferred stock and loan agreements; broad management discretion over proceeds; market overhang from continuous ATM issuance; and the possibility that financing may not be available on acceptable terms, jeopardising ongoing operations.
Strategic context. The facility provides funding flexibility without the execution risk or discount typically associated with overnight offerings, yet continuous issuance could pressure the share price given average trading volumes and the relatively low US$1.25 stock price. Operational execution in advancing TVGN 489 and other pipeline assets remains critical to justify ongoing dilution.
JPMorgan Chase Financial Company LLC, guaranteed by JPMorgan Chase & Co., is offering five-year S&P 500 Futures Excess Return Index Uncapped Accelerated Barrier Notes (CUSIP 48136FDM1). The notes are linked to the performance of the S&P 500庐 Futures Excess Return Index and require a $1,000 minimum denomination.
Key economic terms
- Pricing Date: 28 July 2025
- Maturity: 28 June 2030 (single Observation Date 25 June 2030)
- Upside Leverage Factor: 鈮� 1.71 (final level set on pricing date)
- Barrier Amount: 70% of the Initial Value
- Estimated Value: not less than $900 per $1,000 note, lower than issue price
Payment at maturity
- If the Final Value > Initial Value: principal + (principal 脳 Index Return 脳 Leverage Factor).
- If Final Value between Barrier and Initial (inclusive): full principal returned.
- If Final Value < Barrier: principal + (principal 脳 Index Return) 鈥� investors lose more than 30% and up to 100% of principal.
Illustrative total returns range from +111.15% (Index +65%) to 鈥�100% (Index 鈥�100%).
Risk highlights
- Principal risk: no principal guarantee below the 70% barrier.
- Credit risk: repayment depends on JPMorgan Chase Financial Company LLC and the guarantor JPMorgan Chase & Co.
- No coupons: investors receive no periodic interest.
- Liquidity: JPMS may repurchase in the secondary market but is not obligated; exit prices could be well below par.
- Structural complexities: index differs from spot S&P 500 due to futures roll, potential negative carry and trading halts.
- Estimated value gap: internal valuation is expected to be at least $900, reflecting upfront fees and hedging costs.
- Potential conflicts: JPMorgan acts as calculation agent, hedger and market-maker.
The offering is being made under an effective shelf registration statement; investors should review the prospectus, product supplement and preliminary pricing supplement before investing.
FAQ
What is the current stock price of Shake Shack (SHAK)?
What is the market cap of Shake Shack (SHAK)?
What is Shake Shack Inc known for?
How does Shake Shack differentiate itself from other fast-food chains?
What is the primary business model of Shake Shack Inc?
How does Shake Shack ensure the quality of its food?
What role does community play in Shake Shack's brand identity?
How does Shake Shack incorporate innovation in its menu offerings?
What are the key segments in Shake Shack鈥檚 product lineup?
How does Shake Shack maintain operational efficiency?
